Personalized mRNA cancer vaccine clears Phase 3 hurdle in melanoma
TL;DR Summary
A patient-specific mRNA vaccine (intismeran autogene) combined with Keytruda met the Phase 3 primary endpoint in a 1,137-patient trial of resected melanoma, improving recurrence-free survival and potentially paving the way for the first FDA-approved mRNA-based cancer therapy; full data are to be presented later, with safety profile consistent with Keytruda.
Topics:business#cancer-immunotherapy#health#keytruda#melanoma#personalized-mrna-vaccine#phase-3-trial
- Cancer treatment could face landmark moment with promising vaccine washingtonpost.com
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial CNBC
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial STAT
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano Yahoo Finance
- Moderna-Merck MRNA Shot Helped Cut Melanoma Recurrence in Big Trial Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
6
Time Saved
5 min
vs 6 min read
Condensed
95%
1,029 → 50 words
Want the full story? Read the original article
Read on washingtonpost.com